苦参素治疗对慢乙肝患者TGF - β1、TNF -α、HA、PcⅢ水平的影响(英文)

Effect of matrine on levels of TGF-β_1, TNF-α,HA and PcⅢ in sera of chronic hepatitis B patients

目的 探讨苦参素在慢性乙型肝抗肝纤维化的作用机理。方法 采用ELISA和RIA方法对治疗Ⅰ组和治疗Ⅱ组 (苦参素组 )治疗前及治疗 6月后的慢性肝炎轻度、肝炎中度、肝炎重度及肝硬化 2 4 6例患者血清转化生长因子 β1(TGF - β1)、肿瘤坏死因子α(TNG -α)、透明质酸 (HA)、Ⅲ型前胶原 (PaⅢ )含量进行测定 ,并设立 35例健康献血人员作为正常组。结果 治疗前两组患者血清TGF - β1、TNF -α、HA、PcⅢ均不同程度的升高 ,与正常组相比差异显著 (P <0 .0 5或P <0 .0 1) ;治疗后均有不同程度的降低 ,治疗Ⅱ组治疗后与治疗前相比明显下降 (P <0 .0 5或P <0 .0 1) ,并与治疗Ⅰ组在慢性肝炎中度、肝炎重度、肝硬化间差异显著(P <0 .0 5或P <0 .0 1)。结论 苦参具有逆转肝纤维的作用 ,有部分机制通过抑制TGF - β1、TNF -α的分泌 ,并且具有良好的耐受性。

Objective:To investigate the mechanism of therapeutic effect of matrine on liver fibrosis in patients with chronic hepatitis B.Methods:The levels of transforming growth factor-β 1 ( TGF-β 1), tumor necrosis factor-α (TNF-α), hyaline acid (HA) and type Ⅲ procollagen (PcⅢ) were detected in 246 patients with chronic mild, moderate, severe hepatitis B and liver cirrhosis in group Ⅰ and group Ⅱ (matrine group) before treatment and three months after treatment by ELISA and RIA, and 35 healthy donors served as normal group.Results:The serum levels of TGF-β 1, TNF-α, HA and PcⅢ in patients with chronic hepatitis B increased notably than those of normal groups, and difference was obvious between CHB and normal group (P<0.05 or P<0.01) .The serum levels of TGF-β 1, TNF-α, HA and PcⅢ decreased notably than those before treatment, after treatment with matrine. The serum levels of TGF-β 1, TNF-α, HA and PcⅢ significantly decreased compared with the ones before treatment (P<0.05 or P<0.01), and there was significant difference in patients with chronic moderate, severe hepatitis B and liver cirrhosis between post treatment group Ⅱ and post treatment group Ⅰ (P<0.05 or P<0.01).Conclusions: Matrine reverses the liver fibrosis with therapeutic effect on liver fibrosis, this is partly by inhibiting secretions of TGF-β 1 and TNF-α, and the patients have a good tolerance to it.